Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.50 Contact Hours.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Bayer Healthcare Pharmaceuticals Inc.
Burst CME™ Plus - Matching Treatment to Patient in PAH
Release Date: February 9, 2021
Expiration Date: February 9, 2022
Pulmonary arterial hypertension (PAH), which eventually leads to right-sided heart failure, is a devastating progressive disease that poses a considerable burden on quality of life. Advancements in drug therapy and patient care over the past 10 years have improved morbidity and mortality rates for patients with PAH. Though new therapies have played a major role in this improvement, there remains a need to ensure timely diagnosis, improve therapeutic selection and strategies, and continue to enhance overall patient care.
This engaging, multimedia program integrates video commentary from an expert thought leader, Victor Tapson, MD, with text-based elements and is designed to provide a concise overview of treatment options for PAH and best practices for therapeutic decision-making.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Bayer Healthcare Pharmaceuticals Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward pulmonologists, primary care clinicians, NPs, PAs, nurses, and other healthcare professionals that treat PAH.
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the latest clinical efficacy and safety data for current and emerging therapeutic agents for the treatment of patients with PAH
- Apply patient-specific considerations to individualize care for patients with PAH
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Professor of Medicine
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Vascular Disease Research
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosures: Grant/Research Support: Actelion, Janssen, Johnson & Johnson, Bayer, United Therapeutics; Consultant: Actelion, Janssen, Johnson & Johnson, Bayer, United Therapeutics; Speaker’s Bureau: Janssen.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.